Advances in the selective c-MET kinase inhibitors: Application of fused [5,6]-Bicyclic nitrogen-containing cores for anticancer drug design
- 20 December 2024
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 284, 117177
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- 4‐{3‐[(Pyridin‐4‐ylmethyl)amino]‐[1,2,4]triazolo[4,3‐b][1,2,4]triazin‐6‐yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulatorArchiv der Pharmazie, 2024
- Small molecule inhibitors targeting the cancersMedcomm, 2022
- Recent developments of c‐Met as a therapeutic target in hepatocellular carcinomaHepatology, 2017
- Apigenin Inhibits Cancer Stem Cell‐Like Phenotypes in Human Glioblastoma Cells via Suppression of c‐Met SignalingPhytotherapy Research, 2016
- Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer CellsThe Prostate, 2016
- Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase InhibitorsJournal of Pharmaceutical Sciences, 2014
- O‐Linked Triazolotriazines: Potent and Selective c‐Met InhibitorsChemMedChem, 2012
- Src and FAK mediate cell–matrix adhesion‐dependent activation of met during transformation of breast epithelial cellsJournal of Cellular Biochemistry, 2009
- C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neuInternational Journal of Cancer, 2004
- Novel mutation in the ATP-binding site of theMET oncogene tyrosine kinase in a HPRCC familyInternational Journal of Cancer, 1999